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:   non‐small‐cell lung cancer
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:   small cell lung cancer
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1. INTRODUCTION {#cas13448-sec-0001}
===============

Sialic acid‐containing glycolipids, gangliosides are highly expressed in GEM/rafts on the plasma membrane of cells.[1](#cas13448-bib-0001){ref-type="ref"}, [2](#cas13448-bib-0002){ref-type="ref"} Gangliosides GM1 and GM2 are generally expressed in lung cancer tissues,[3](#cas13448-bib-0003){ref-type="ref"} whereas GD3 and GD2 are specifically expressed in SCLC cells, based on the expression of GD3 synthase.[3](#cas13448-bib-0003){ref-type="ref"}, [4](#cas13448-bib-0004){ref-type="ref"} In addition, GD2 is expressed in neuroblastoma cells, and is a target molecule for treatment of the disease.[5](#cas13448-bib-0005){ref-type="ref"} Previous studies reported that GD2 enhances malignant phenotypes such as cell proliferation and invasion activity, and anti‐GD2 mAb induces apoptosis in SCLC cells.[3](#cas13448-bib-0003){ref-type="ref"}, [4](#cas13448-bib-0004){ref-type="ref"} However, it is not well known how GD2 promotes malignant phenotypes in SCLC cells.

ASC amino acid transporter 2 (SLC1A5)[6](#cas13448-bib-0006){ref-type="ref"}, [7](#cas13448-bib-0007){ref-type="ref"} is a major glutamine transporter that is highly expressed in several tumors, such as non‐SLCL, clear cell renal cell carcinoma, triple‐negative breast cancer, and neuroblastoma cells.[8](#cas13448-bib-0008){ref-type="ref"}, [9](#cas13448-bib-0009){ref-type="ref"}, [10](#cas13448-bib-0010){ref-type="ref"}, [11](#cas13448-bib-0011){ref-type="ref"}, [12](#cas13448-bib-0012){ref-type="ref"} In triple‐negative breast cancer cells, cell proliferation is increased by glutamine uptake by ASCT2, and the malignant phenotypes were decreased by GPNA, which specifically inhibits glutamine uptake by ASCT2.[11](#cas13448-bib-0011){ref-type="ref"} Moreover, the growth of NSCLC cells injected into the flank of nude mice was significantly suppressed by GPNA.[13](#cas13448-bib-0013){ref-type="ref"}

Mammalian target of rapamycin complex 1 is deeply associated with malignant phenotypes of cancer cells. The loss of p53, a very common event in cancer, promotes activation of mTORC1 and malignant phenotypes.[14](#cas13448-bib-0014){ref-type="ref"}, [15](#cas13448-bib-0015){ref-type="ref"} Recently, it was reported that glutamine is a key amino acid to activate mTORC1 through Arf1 in lysosome lumen.[16](#cas13448-bib-0016){ref-type="ref"}, [17](#cas13448-bib-0017){ref-type="ref"} A downstream factor of mTORC1, p70 S6K1, is dephosphorylated by inhibiting glutamine uptake in triple‐negative breast cancer cells.[11](#cas13448-bib-0011){ref-type="ref"} Moreover, glutamine uptake by ASCT2 is also required for the activation of mTORC1 for T‐cell differentiation.[18](#cas13448-bib-0018){ref-type="ref"}

Although roles of GD2 in malignant phenotypes of SCLC have been analyzed, there is no information about molecules interacting with GD2 in GEM/rafts. To date, it has been reported that GD3 interacts with membrane proteins in melanomas and glioma cells, which promotes malignant phenotypes of individual cancer cells.[19](#cas13448-bib-0019){ref-type="ref"}, [20](#cas13448-bib-0020){ref-type="ref"} In this study, we aimed to reveal the molecular mechanisms by which GD2 expressed on the membrane of SCLC cells induces malignant phenotypes, then used EMARS combined with MS[21](#cas13448-bib-0021){ref-type="ref"}, [22](#cas13448-bib-0022){ref-type="ref"} to address this aim. By EMARS combined with MS analysis, we identified molecules associating with GD2 in GEM/rafts of SCLC cells, and analyzed the interaction between GD2 and these target molecules. Consequently, we identified ASCT2 as a molecule associating with GD2 in SCLC cells. Here, we show the roles of ASCT2 in GD2^+^ SCLC cells, and the mechanisms by which GD2 and ASCT2 co‐operate in the enhancement of malignant phenotypes of SCLC cells.

2. MATERIALS AND METHODS {#cas13448-sec-0002}
========================

2.1. Cell culture {#cas13448-sec-0003}
-----------------

D‐8, D‐13, and D‐18 were SK‐LC‐17 transfected with GD3 synthase cDNA, and C‐2, C‐6, and C‐8 were SK‐LC‐17 transfected with a control vector.[3](#cas13448-bib-0003){ref-type="ref"}, [23](#cas13448-bib-0023){ref-type="ref"} Human α‐2,8‐sialyltransferase (GD3 synthase) cDNA clone pD3T‐31 was subcloned into pMIKneo vector (Assoc. Prof. Kazuo Maruyama, Dep. Hygiene, Tokyo Medical Dental University, Tokyo, Japan) to obtain the pMIKneo/D3T‐31.[23](#cas13448-bib-0023){ref-type="ref"} SK‐LC‐17 cell lines used for cDNA transfection were plated on a 60‐mm plastic tissue culture plate at a density of 6 × 10^5^ cells/4 mL/plate. After 24 hours, the medium was removed and the cells were washed twice with serum‐free DMEM. The pMIKneo/D3T‐31 vector (4 μg) was mixed with Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA), then added to the cells in the plate. After 6 hours of incubation, the medium was changed to the regular one as described above. Stable transfectants were selected with 250 μg/mL G418. Other SCLC cell lines, NCI‐N417 and ACC‐LC‐171, were described previously.[3](#cas13448-bib-0003){ref-type="ref"} These cell lines were cultured in RPMI‐1640 supplemented with 10% FCS and G418 (250 μg/mL) at 37°C in a humidified atmosphere containing 5% CO~2~.

2.2. Construction and transfection of expression vectors {#cas13448-sec-0004}
--------------------------------------------------------

GD3 synthase cDNA was previously described.[23](#cas13448-bib-0023){ref-type="ref"} The cDNA of human ASCT2 was subcloned into pCMV‐Tag 3 vector. The pCMV‐Tag 3 vector is used to induce transient expression of an N‐terminal c‐myc fusion protein in SK‐LC‐17 cells.

2.3. Antibodies and reagents {#cas13448-sec-0005}
----------------------------

Mouse anti‐GD3 mAb (R‐24) was obtained from Dr. L.J. Old (Memorial Sloan Kettering Cancer Center, New York, NY, USA). Mouse anti‐GD2 mAb (220‐51) was generated in our laboratory. Rabbit anti‐flotillin‐1 antibody, rabbit anti‐caveolin‐1 antibody, mouse anti‐CD109 mAb, rabbit anti‐PDGFRα antibody, goat anti‐ASCT2 antibody, and mouse anti‐c‐myc antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti‐ASCT2 antibody, rabbit anti‐phospho‐mTOR antibody (Ser2448), rabbit anti‐mTOR mAb, mouse anti‐phospho‐p70 S6 kinase mAb (Thr389), rabbit anti‐p70 S6 kinase mAb, rabbit anti‐S6 ribosomal protein mAb, rabbit anti‐phospho‐S6 ribosomal protein mAb (Ser235/Ser236), rabbit anti‐EphA2 mAb, and rabbit anti‐CD44 antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Goat anti‐urokinase plasminogen activator surface receptor antibody was purchased from R&D Systems (Minneapolis, MN, USA). Rabbit anti‐c‐myc antibody was purchased from Sigma‐Aldrich (St. Louis, MO, USA). Rabbit anti‐ASCT2 conjugated with Alexa 488 was purchased from Bioss (Woburn, MA, USA).

2.4. Flow cytometry {#cas13448-sec-0006}
-------------------

Surface expression of ganglioside GD2, GD3, and ASCT2 on SK‐LC‐17 transfectants was analyzed by FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) using anti‐GD2 mAb (220‐51), anti‐GD3 mAb (R24), and goat anti‐ASCT2 antibody. Cells (8.0 × 10^5^) were trypsinized and washed with PBS three times. The cells were incubated with the primary antibodies for 60 minutes on ice, then incubated with FITC‐conjugated anti‐mouse IgG antibody and anti‐goat IgG antibody for 45 minutes. After washing with PBS, relative expression levels of GD2, GD3, and ASCT2 were analyzed by FACSCalibur.

2.5. Enzyme‐mediated activation of radical sources and MS analysis {#cas13448-sec-0007}
------------------------------------------------------------------

The EMARS reactions and MS analysis were carried out as described previously.[21](#cas13448-bib-0021){ref-type="ref"}, [22](#cas13448-bib-0022){ref-type="ref"} Briefly, D‐13 and D‐18 cells (5.0 × 10^5^) were treated with 10 μg/mL HRP‐conjugated monovalent anti‐GD2 mAb (220‐51) in 2% BSA/PBS at room temperature for 20 minutes. After washing with PBS, cells were incubated with FA solution diluted in PBS (0.1 mmol/L FA/PBS) at room temperature for 15 minutes with light shielding. After washing twice with PBS, treated cells were scraped with 100 mmol/L Tris‐HCl (pH 7.4) and 1 mmol/L PMSF. Molecules labeled with FITC were immunoprecipitated with an anti‐FITC antibody and served for MS analysis. Horseradish peroxidase‐conjugated monovalent anti‐GD2 mAb (220‐51) was prepared using a Peroxidase Labeling Kit‐SH (Dojindo, Kumamoto, Japan). Immunoprecipitates were dissolved in MS sample buffers (12 mmol/L sodium deoxycholate, 12 mmol/L sodium lauroylsarcosine, and 100 mmol/L Tris‐HCl \[pH 8.0\]), boiled at 95°C, and centrifuged at 20 000 *g* for 15 minutes. The supernatants underwent reduction with dithiothreitol and alkylation with iodoacetamide. The samples were diluted fivefold with 50 mmol/L ammonium bicarbonate and digested by Lys‐C (Wako, Osaka, Japan) for 3 hours, then by trypsin for 8 hours at 37°C. They were desalted and concentrated with C18 StageTips (Thermo Fisher Scientific, Waltham, MA, USA). Mass spectrometry was undertaken using an LTQ‐Orbitrap‐XL MS mass spectrometer (Thermo Fisher Scientific) system combined with a Paradigm MS4 high‐performance TLC system (Michrom BioResources, Auburn, CA, USA). Tandem MS spectra were submitted to the program Mascot 2.3 (Matrix Science, Boston, MA, USA) and X! Tandem (The Global Proteome Machine; <http://www.thegpm.org/tandem/>) for MS/MS ion search. Mascot was set up to search the Sprot_2013_6 database (selected for *Homo sapiens*, 20, 249) assuming the digestion enzyme trypsin.

2.6. Western blot analysis {#cas13448-sec-0008}
--------------------------

After washing with PBS three times, cells were lysed by cell lysis buffer (20 mmol/L Tris‐HCl \[pH 7.5\], 150 mmol/L NaCl, 1 mmol/L Na~2~EDTA, 1 mmol/L EGTA, 1% Triton X‐100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β‐glycerophosphate, 1 mmol/L Na~3~VO~4~, and 1 μg/mL leupeptin) (Cell Signaling Technology) supplemented with a protease inhibitor cocktail (Merck, Darmstadt, Germany). Cell lysates were sonicated briefly, and were centrifuged at 14 000 *g* for 10 minutes to remove insoluble materials. Proteins in supernatants were measured by the DC protein assay (Bio‐Rad, Hercules, CA, USA), and proteins were separated in SDS‐PAGE using 10% gels. Separated proteins were transferred onto an Immobilon‐P membrane (EMD Millipore, Billerica, MA, USA), and blots were incubated with 5% skim milk in PBS including 0.05% Tween‐20 for blocking. The membrane was probed with primary antibodies and HRP‐labeled secondary antibodies sequentially, and bound conjugates on the membrane were visualized with an Enhanced Chemiluminescence detection system (PerkinElmer, Waltham, MA, USA).

2.7. Thin‐layer chromatography immunostaining {#cas13448-sec-0009}
---------------------------------------------

Immunoprecipitates were extracted by treating with chloroform / methanol (2:1, v/v). After evaporation of solvents under N~2~ gas stream, lipids were dissolved in distilled water and loaded to Sep‐Pak C18 cartridges (Waters, Milford, MA, USA). After washing with distilled water, lipids were eluted by methanol and a chloroform/methanol mixture (2:1 and 1:1, v/v) sequentially. The extracts were dried under an N~2~ gas stream and dissolved in 30 μL chloroform/methanol (2:1, v/v). Extracted lipids were separated using high‐performance TLC plates (Merck). These lipids were developed using a solvent system of chloroform/methanol/0.22% CaCl~2~ (55:45:10, v/v/v) and blotted onto a PVDF membrane (Atto, Tokyo, Japan) using TLC Thermal Blotter (AC‐5970; Atto). After blocking with 3% BSA in PBS, the membrane was incubated with an anti‐GD2 mAb (220‐51) or an anti‐GD3 mAb (R24) for 60 minutes. Biotin‐conjugated anti‐mouse IgG antibody was then incubated for 30 minutes, and ABC reagent (Vector Laboratories, Burlingame, CA, USA) was incubated for 30 minutes. Bound conjugates on the membrane were visualized with an Enhanced Chemiluminescence detection system (PerkinElmer).

2.8. Immunoprecipitation {#cas13448-sec-0010}
------------------------

Cells (3.0 × 10^6^) were seeded on 10‐cm dishes. After 24 hours, c‐myc‐tag ASCT2 was transfected into cells using Lipofectamine 2000 (Thermo Fisher Scientific) and incubated for 48 hours. Cells were lysed with lysis buffer containing 1% Triton X‐100. Lysates were centrifuged at 14 000 *g* for 10 minutes at 4°C to remove insoluble materials, and were immunoprecipitated with anti‐c‐myc antibody at 4°C overnight with rotation. Protein G‐Sepharose (GE Healthcare, Little Chalfont, UK) was added and rotated at 4°C for 2 hours. The beads were washed three times with IP buffer (50 mmol/L Tris‐HCl \[pH 7.4\], 150 mmol/L NaCl, and 1 mmol/L Na~3~VO~4~) containing 0.5% Triton X‐100, and the precipitated proteins were separated with SDS‐PAGE to be used for immunoblotting.

2.9. Quantitative PCR {#cas13448-sec-0011}
---------------------

Extraction of RNAs was carried out using TRIzol reagent (Ambion by Life Technologies, Carlsbad, CA, USA) following the manufacturer\'s protocol. cDNA was generated using oligo dT primer and Moloney murine leukemia virus reverse transcriptase (Invitrogen, San Diego, CA, USA). The qPCR was carried out using a DyNAmo SYBR Green qPCR Kit (Thermo Fisher Scientific) and CFX Connect Real‐Time System (Bio‐Rad). Primers used in this study were: ASCT2 forward, 5′‐CTCCTTGATCCTGGCTGTGG‐3′; and reverse, 5′‐CCCAGAGCGTCACCTTCTAC‐3′.

2.10. Sucrose density gradient fractionation of Briji35 extracts {#cas13448-sec-0012}
----------------------------------------------------------------

Sucrose density gradient fractionation was carried out as reported previously with modification.[24](#cas13448-bib-0024){ref-type="ref"} Briefly, cells (1.0 × 10^7^) were lysed by MES + NaCl + EDTA (MNE) buffer containing 1% Briji35. After removing insoluble materials by centrifugation at 14 000 *g* for 10 minutes, lysates were dounced 10 times with a Digital Homogenizer (As One, Osaka, Japan). The lysates were mixed with an equal volume of 80% sucrose in MNE buffer, and stepwise gradient was prepared by overlaying 30% sucrose in MNE buffer followed by a final layer of 5% sucrose in MNE buffer. The gradient was formed by centrifugation for 14‐16 hours at 4°C at 100 000 *g* using an MLS50 rotor (Beckman Coulter, Brea, CA, USA). Fractions of 500 μL were separated from the top of the gradient and were used for Western blot analyses.

2.11. Isolation of cell surface proteins by biotin labeling {#cas13448-sec-0013}
-----------------------------------------------------------

Biotin labeling and isolation of cell surface proteins were carried out with a Cell Surface Protein Isolation Kit (Thermo Fisher Scientific), following the manufacturer\'s protocol. Briefly, cells (1.0 × 10^7^) were washed using ice‐cold PBS three times, and surface proteins were labeled with sulfo‐NHS‐SS‐Biotin for 30 minutes. Subsequently, cells were lysed in cell lysis buffer (20 mmol/L Tris‐HCl \[pH 7.5\], 150 mmol/L NaCl, 1 mmol/L Na~2~EDTA, 1 mmol/L EGTA, 1% Triton X‐100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β‐glycerophosphate, 1 mmol/L Na~3~VO~4~, and 1 μg/mL leupeptin) (Cell Signaling Technology) supplemented with a protease inhibitor cocktail (Merck) and spun at 14 000 *g* at 4°C to remove insoluble materials. Biotin‐labeled surface proteins were captured on NeutrAvidin agarose resin at room temperature for 1 hours. After the resin was washed, proteins bound to the resin were eluted with 1× SDS‐PAGE sample buffer, and analyzed by Western blotting.

2.12. Immunocytochemistry {#cas13448-sec-0014}
-------------------------

Cells (2 × 10^5^) were plated on a glass‐bottomed dish (Iwaki, Tokyo, Japan) precoated with 0.01% poly‐L‐lysine (Sigma‐Aldrich) and incubated for 24 hours in RPMI‐1640 supplemented with 10% FCS. Cells were transfected with c‐myc‐tag ASCT2 cDNA using Lipofectamine 2000 (Thermo Fisher Scientific) and incubated for 24 hours. After washing three times with PBS, cells were fixed with 4% paraformaldehyde in PBS for 10 minutes at room temperature. Dishes were then blocked with 10% donkey serum albumin in PBS for 1 hours and incubated with anti‐GD2 mAb (220‐51) and anti‐c‐myc antibody diluted in 0.5% donkey serum albumin in PBS. After incubation with primary antibodies for 1 hour at room temperature, dishes were washed with PBS and incubated with an Alexa 568‐conjugated anti‐mouse IgG antibody and Alexa 488‐conjugated anti‐rabbit IgG antibody (Invitrogen) in 0.5% donkey serum albumin in PBS for 1 hour at room temperature. After washing dishes with PBS, DAPI staining was carried out, and then cells were observed under a confocal microscope (LSM 700; Carl Zeiss, Oberkochen, Germany).

2.13. Proximity ligation assay {#cas13448-sec-0015}
------------------------------

Proximity ligation assay was carried out using a Duolink in situ PLA kit (Sigma‐Aldrich), following the manufacturer\'s protocol. Briefly, cells (2 × 10^5^) were plated on a glass‐bottomed dish (Iwaki) precoated with 0.01% poly‐L‐lysine (Sigma‐Aldrich), and incubated for 24 hours in RPMI‐1640 supplemented with 10% FCS. Cells were transfected with c‐myc‐tag ASCT2 cDNA using Lipofectamine 2000 (Thermo Fisher Scientific) and incubated for 24 hours. After washing three times with PBS, cells were fixed with 4% paraformaldehyde in PBS for 10 minutes at room temperature. Dishes were then blocked with 10% donkey serum albumin in PBS for 1 hour and incubated with anti‐GD2 mAb and anti‐c‐myc antibody diluted in 0.5% donkey serum albumin in PBS. Duolink in situ PLA probes anti‐mouse PLUS and anti‐rabbit MINUS were added and incubated for 1 hour at 37°C. Ligation solution was added, followed by incubation for 30 minutes at 37°C. Amplification was carried out for 100 minutes at 37°C. Cells were observed under a confocal microscope (Fluoview FV10i; Olympus, Tokyo, Japan).

2.14. Cell proliferation assay {#cas13448-sec-0016}
------------------------------

Cells (2.0 × 10^3^) were plated in 96‐well plates and incubated for 1‐5 days in RPMI‐1640 (containing no glutamine) supplemented with 10% dialyzed FCS and glutamine (5 mmol/L). After culturing for 1‐5 days, 20 μL MTT solution (5 mg/mL in PBS) was added and incubated for 4 hours at 37°C. The reaction was stopped by adding 1‐propanol containing 0.4% HCl and 0.1% NP‐40. The absorption values at 590 nm were then determined using an automatic plate reader (ImmunoMini NJ‐2300; Nalgene Nunc, NY, USA).

2.15. \[^3^H\]‐glutamine uptake {#cas13448-sec-0017}
-------------------------------

The \[^3^H\]‐glutamine uptake experiment was carried out as described previously, with modification.[25](#cas13448-bib-0025){ref-type="ref"} Briefly, cells (2.0 × 10^5^) were cultured in serum‐free RPMI‐1640 supplemented with 1 nmol/L tritium‐labeled glutamine for 1 minute, and cells were washed using ice‐cold PBS three times and lysed. Radioactivity was counted by a liquid scintillation counter (Beckman Coulter).

2.16. In vitro migration assay {#cas13448-sec-0018}
------------------------------

The confluent cells were scratched with a 1000‐μL disposable plastic pipette tip and gently washed using RPMI‐1640 twice. The cells were cultured in RPMI‐1640 containing 10% FCS supplemented with or without 1 mmol/L GPNA. The cells were allowed to migrate towards the wound space for 16 hours, then migration rates were measured by taking pictures under a microscope (migration area of 16‐0 hours).

2.17. Knockdown of ASCT2 in SK‐LC‐17 transfectants {#cas13448-sec-0019}
--------------------------------------------------

The ASCT2‐specific siRNAs \#1, \#2, and \#3 (Sigma‐Aldrich) or scramble siRNA (200 pmol) were transfected into cells (1.0 × 10^6^) by Lipofectamine 2000 (Thermo Fisher Scientific).

2.18. Statistical analysis {#cas13448-sec-0020}
--------------------------

Mean values were calculated using an unpaired Student\'s two‐tailed *t*‐test. *P*‐values of \<.05 were considered statistically significant.

3. RESULTS {#cas13448-sec-0021}
==========

3.1. Enzyme‐mediated activation of radical sources/MS in GD2^+^ SK‐LC‐17 cells identifies five candidate molecules {#cas13448-sec-0022}
------------------------------------------------------------------------------------------------------------------

GD2 is specifically expressed on SCLC cells, and promotes malignant phenotypes. In order to analyze the roles of GD2 in SCLC cells, we transfected GD3 synthase cDNA into GD2^−^ SK‐LC‐17 cells, and established SK‐LC‐17 transfectants D‐8, D‐13, and D‐18 highly expressing GD3 and GD2[3](#cas13448-bib-0003){ref-type="ref"} (Figures [1](#cas13448-fig-0001){ref-type="fig"}A, [S1](#cas13448-sup-0001){ref-type="supplementary-material"}). C‐2, C‐6, and C‐8 are GD2^−^ SK‐LC‐17 transfectants (Figures [1](#cas13448-fig-0001){ref-type="fig"}A, [S1](#cas13448-sup-0001){ref-type="supplementary-material"}). Tumor‐specific gangliosides coordinately work with plasma membrane proteins in cancer cells, which leads to enhancement of malignant phenotypes.[19](#cas13448-bib-0019){ref-type="ref"}, [20](#cas13448-bib-0020){ref-type="ref"} However, it is not well known what kind of plasma membrane proteins work together with GD2 in SCLC cells. To address this issue, we tried to identify GD2‐associating molecules by EMARS‐MS in GD2^+^ SK‐LC‐17 transfectants, D‐13 and D‐18 (a scheme of EMARS is shown in Figure [1](#cas13448-fig-0001){ref-type="fig"}B). In this method, molecules located within a 100‐200‐nm diameter of GD2 were labeled with FITC by radical reaction of an aryl azide functional group.[21](#cas13448-bib-0021){ref-type="ref"}, [22](#cas13448-bib-0022){ref-type="ref"} Then FITC‐labeled molecules were collected by immunoprecipitation using an anti‐FITC antibody (Figure [1](#cas13448-fig-0001){ref-type="fig"}C). These EMARS‐IP samples were applied to liquid chromatography--MS/MS analyses to identify the labeled molecules. We succeeded in identifying 15 plasma membrane proteins as GD2‐associating molecules in D‐13 and D‐18 (Figure [1](#cas13448-fig-0001){ref-type="fig"}D, Table [1](#cas13448-tbl-0001){ref-type="table-wrap"}). Among the common GD2‐associating molecules between D‐13 and D‐18, we focused on five candidate molecules, ASCT2, CD109, urokinase plasminogen activator surface receptor, CD44, and EphA2, because the scores of these molecules were high (protein identification probabilities were more than 99%), and they were classified into membrane molecules.

![Enzyme‐mediated activation of radical sources (EMARS)/mass spectrometry (MS) in ganglioside GD2^+^ SK‐LC‐17 small‐cell lung cancer cells identified five candidate molecules. A, Expression levels of GD2 in SK‐LC‐17 transfectants were analyzed by flow cytometry. B, Scheme of EMARS combined with liquid chromatography (LC)/MS. EMARS reaction was carried out using HRP‐conjugated anti‐GD2 mAb (α‐GD2 mAb‐HRP) as an anchor, and fluorescein‐LC‐ASA. Molecules labeled with FITC by EMARS reaction were immunoprecipitated using rabbit anti‐FITC antibody, and the samples were applied to LC/MS. C, Immunoprecipitates in EMARS reaction were analyzed by Western blotting with a goat anti‐FITC antibody. Control (none) was prepared without anti‐GD2 mAb (220‐51). D, Number of identified plasma membrane proteins to be associated with GD2 by EMARS shown in Venn diagrams. We considered that protein identification probabilities are \>50%. IB, immunoblot; IP, immunoprecipitant](CAS-109-141-g001){#cas13448-fig-0001}

###### 

Candidate molecules associating with ganglioside GD2 as defined in enzyme‐mediated activation of radical sources--mass spectrometry

  \#   Protein name                                       Accession     Probabilities         
  ---- -------------------------------------------------- ------------- --------------- ----- -----
  1    Adenylyl cyclase‐associated protein 1              CAP1_HUMAN    52              100   100
  2    Elongation factor 1 ‐α1                            EF1A1_HUMAN   50              100   100
  3    Ubiquitin‐40S ribosomal protein S27a               RS27A_HUMAN   18              100   100
  4    ADP/ATP translocase 2                              ADT2_HUMAN    33              100   100
  5    Keratin, type II cytoskeletal 8                    K2C8_HUMAN    54              100   100
  6    CD109                                              CD109_HUMAN   162             100   100
  7    Ephrin type‐A receptor 2                           EPHA2_HUMAN   108             100   100
  8    Desmoglein‐2                                       DSG2_HUMAN    122             100   100
  9    Phosphate carrier protein, mitochondrial           MPCP_HUMAN    40              100   99
  10   Urokinase plasminogen activator surface receptor   UPAR_HUMAN    37              100   99
  11   Glyceraldehyde‐3‐phosphate dehydrogenase           G3P_HUMAN     36              99    100
  12   CD44 antigen                                       CD44_HUMAN    82              99    100
  13   ASC amino‐acid transporter 2                       AAAT_HUMAN    57              99    100
  14   Syndecan‐2                                         SDC2_HUMAN    22              83    90
  15   Ig κ chain V‐I region Roy                          KV116_HUMAN   12              97    93

M.W., molecular weight.

We considered that scores (probabilities) of the molecules were \>50, and common candidate molecules associating with GD2 between D‐13 and D‐18 are shown.

John Wiley & Sons, Ltd

3.2. ASC amino acid transporter 2 associated with GD2 in GEM/rafts {#cas13448-sec-0023}
------------------------------------------------------------------

Next, we examined which candidate molecules more specifically work with GD2 in SCLC cells. Gangliosides are mainly expressed on the plasma membrane and localized in GEM/rafts,[1](#cas13448-bib-0001){ref-type="ref"}, [2](#cas13448-bib-0002){ref-type="ref"} and we predicted that these five candidate molecules are highly expressed in GEM/rafts. Therefore, we fractionated detergent extracts from SK‐LC‐17 transfectants by sucrose density‐gradient ultracentrifugation,[24](#cas13448-bib-0024){ref-type="ref"} and analyzed levels of ASCT2, CD109, urokinase plasminogen activator surface receptor, CD44, and EphA2 expression in the raft fractions of SK‐LC‐17 transfectants (Figure [2](#cas13448-fig-0002){ref-type="fig"}A). Interestingly, ASCT2 was highly expressed in GEM/rafts of GD2^+^ SK‐LC‐17 transfectants, whereas it was only minimally detected in GEM/rafts of GD2^−^ SK‐LC‐17 transfectants (Figures [2](#cas13448-fig-0002){ref-type="fig"}A, [S2](#cas13448-sup-0002){ref-type="supplementary-material"}). The expression level of EphA2 in the raft fractions of GD2^+^ SK‐LC‐17 transfectants was also higher than in GD2^−^ SK‐LC‐17 transfectants (Figures [2](#cas13448-fig-0002){ref-type="fig"}A, [S2](#cas13448-sup-0002){ref-type="supplementary-material"}). Although EphA2 has emerged to be strongly associated with malignant phenotypes in glioma cells and lung cancer cells,[26](#cas13448-bib-0026){ref-type="ref"}, [27](#cas13448-bib-0027){ref-type="ref"} the function of ASCT2 has been poorly understood in SCLC cells. Therefore, we focused on ASCT2, and studied the association between ASCT2 and GD2. We selected C‐2, C‐8, D‐8, and D‐13 clones, because expression levels of ASCT2 in GEM/rafts were very different among them. Surprisingly, total expression levels of ASCT2 in all SK‐LC‐17 transfectants were not considerably different (Figure [2](#cas13448-fig-0002){ref-type="fig"}B). In addition, expression levels of ASCT2 on the plasma membrane among SK‐LC‐17 transfectants were not largely different (Figure [S3](#cas13448-sup-0003){ref-type="supplementary-material"}).

![ASC amino acid transporter 2 (ASCT2) associated with ganglioside GD2 in glycolipid‐enriched microdomain (GEM)/rafts. A, Fractionation of 1% Briji35 extracts from GD2^+^ SK‐LC‐17 transfectants was carried out by sucrose density gradient ultracentrifugation. Cells (1.0 × 10^7^) were lysed by MES + NaCl + EDTA (MNE) buffer containing 1% Briji35. The lysates were mixed with an equal volume of 80% sucrose in MNE buffer, and stepwise gradient was prepared by overlaying 30% sucrose in MNE buffer followed by a final layer of 5% sucrose in MNE buffer. The gradient was formed by ultracentrifugation for 14‐16 h at 4°C at 100 000 *g*. Fractions of 500 μL were separated from the top of the gradient and used for Western blotting. Caveolin‐1 and flotillin‐1 are GEM/raft markers. B, Total expression levels of ASCT2 were analyzed by Western blotting using an anti‐ASCT2 antibody (left panel). N‐linked glycosylation was deleted using N‐glycosidase F. Expression levels of ASCT2 mRNA were analyzed by RT--quantitative PCR (right panel). Expression levels of ASCT2 mRNA were normalized by the *GAPDH* gene. C, Results of immunoprecipitation (IP)--immunoblotting (IB) experiments. Cells (1.0 × 10^6^) were transfected with c‐myc‐tag ASCT2 cDNA and incubated for 48 h. Cells were lysed by lysis buffer containing 1% Triton X‐100, and c‐myc‐tag ASCT2 was immunoprecipitated using an anti‐c‐myc antibody. Total cell lysate was used as input. D, After immunoprecipitation, thin‐layer chromatography (TLC) immunostaining was undertaken using anti‐GD2 mAb (220‐51) to detect GD2. Bovine brain gangliosides (BBG, 1.0 μg) and pure GD2 (0.25 μg) were used as standards](CAS-109-141-g002){#cas13448-fig-0002}

Based on high expression of ASCT2 in GEM/rafts, we examined whether ASCT2 binds with GD2. We transfected c‐myc‐tag ASCT2 cDNA into GD2^+^ SK‐LC‐17 cells, and undertook immunoprecipitation and immunoblotting using anti‐c‐myc antibody and anti‐ASCT2 antibody, respectively (Figure [2](#cas13448-fig-0002){ref-type="fig"}C). The IP products with anti‐c‐myc antibody were applied to TLC immunostaining to detect GD2. Consequently, we found that GD2 was co‐precipitated with ASCT2 (Figure [2](#cas13448-fig-0002){ref-type="fig"}D), suggesting molecular complex formation of ASCT2 and GD2. In IP--TLC immunostaining, background was sometimes high, and faint bands were detected in IP with the normal IgG lane if we want to show definite bands of GD2 in ASCT2 precipitates (Figure [2](#cas13448-fig-0002){ref-type="fig"}D). In turn, GD3 was not co‐precipitated with ASCT2 (Figure [S4](#cas13448-sup-0004){ref-type="supplementary-material"}). We tried to further confirm that GD2 was co‐precipitated with ASCT2 in other SCLC cells, NCI‐N417 and ACC‐LC‐171 expressing endogenous GD2 (Figure [S5](#cas13448-sup-0005){ref-type="supplementary-material"}A). We undertook IP--TLC immunostaining (Figure [S5](#cas13448-sup-0005){ref-type="supplementary-material"}B,C). Unfortunately, we did not find that GD2 was co‐precipitated with ASCT2, probably due to poor transfection efficiency (Figure [S5](#cas13448-sup-0005){ref-type="supplementary-material"}B,C). Next, to reveal whether ASCT2 was really a specific molecule to GD2, we examined whether a membrane protein binds with GD2. Previously, we reported that PDGFRα was identified as a molecule associating with GD3 by EMARS‐MS, and interacts with GD3 in glioma cells.[19](#cas13448-bib-0019){ref-type="ref"} In SK‐LC‐17 transfectants, PDGFRα was expressed in the non‐raft fraction (Figure [2](#cas13448-fig-0002){ref-type="fig"}A), and GD2 was not co‐precipitated with PDGFRα (Figure [S6](#cas13448-sup-0006){ref-type="supplementary-material"}). Taking these results together, ASCT2 is specifically expressed in GEM/rafts of GD2^+^ SK‐LC‐17 transfectants, and associated with GD2, thereby promoting malignant phenotypes.

3.3. Colocalization of ASCT2 with GD2 in GEM/rafts {#cas13448-sec-0024}
--------------------------------------------------

Next, we undertook immunofluorescence/double staining to examine whether ASCT2 is colocalized with GD2. c‐Myc‐tag ASCT2 derived from transfected cDNA was detected in a restricted portion of the cytoplasm and plasma membrane. It was colocalized with GD2 on the plasma membrane of GD2^+^ SK‐LC‐17 transfectants (Figure [3](#cas13448-fig-0003){ref-type="fig"}A). As for endogenous ASCT2, we found that it was also colocalized with GD2 (Figure [S7](#cas13448-sup-0007){ref-type="supplementary-material"}). As caveolin‐1 is a GEM/raft marker, we examined whether c‐myc‐tag ASCT2 was colocalized with caveolin‐1. As a result, we found that c‐myc‐tag ASCT2 was colocalized with caveolin‐1 on the plasma membrane in GD2^+^ SK‐LC‐17 transfectants (Figure [3](#cas13448-fig-0003){ref-type="fig"}B). Although we described that GD2 was not precipitated with ASCT2 in other SCLC cell lines, NCI‐N417 and ACC‐LC‐171 (Figure [S5](#cas13448-sup-0005){ref-type="supplementary-material"}B,C), we found that GD2 was colocalized with both endogenous and exogenous ASCT2 (Figure [S8](#cas13448-sup-0008){ref-type="supplementary-material"}).

![ASC amino acid transporter 2 (ASCT2) colocalized with ganglioside GD2 in glycolipid‐enriched microdomain/rafts. A, GD2 and c‐myc‐tag ASCT2 were immunostained simultaneously. SK‐LC‐17 transfectants were transfected with c‐myc‐tag ASCT2 cDNA. Cells were double‐immunostained with an anti‐c‐myc antibody and an anti‐GD2 mAb (220‐51). After incubation with Alexa 488‐conjugated anti‐rabbit IgG antibody and Alexa 568‐conjugated anti‐mouse IgG antibody as secondary antibodies, cell nuclei were stained with DAPI, and results were observed under a confocal microscope. Scale bar = 10 μm (left) and 2 μm (right, high magnification). B, GD2^+^ SK‐LC‐17 transfectants were double‐immunostained with an anti‐c‐myc antibody and an anti‐caveolin‐1 antibody. After incubation with Alexa 488‐conjugated anti‐mouse IgG antibody and Alexa 568‐conjugated anti‐rabbit IgG antibody as secondary antibodies, cell nuclei were stained with DAPI. Scale bar = 20 μm (left) and 2 μm (right, high magnification). Areas of high magnification indicated by arrows](CAS-109-141-g003){#cas13448-fig-0003}

This result of the double immunofluorescence study was not enough to confirm a close association between GD2 and ASCT2. Therefore, we undertook the PLA and showed a close association between them (Figure [S9](#cas13448-sup-0009){ref-type="supplementary-material"}). Moreover, GD2 and ASCT2 were also closely associated in NCI‐N417 and ACC‐LC‐171 cells (Figure [S10](#cas13448-sup-0010){ref-type="supplementary-material"}). These data clearly showed that ASCT2 was colocalized with GD2 in GEM/rafts in GD2^+^ SK‐LC‐17 transfectants, and suggested that ASCT2 was also closely associated with GD2 in NCI‐N417 and ACC‐LC‐171 cells.

3.4. Malignant phenotypes were suppressed by ASCT2 inhibitor GPNA {#cas13448-sec-0025}
-----------------------------------------------------------------

ASC amino acid transporter 2 is a major glutamine transporter, and promotes malignant phenotypes in several cancer cells.[8](#cas13448-bib-0008){ref-type="ref"}, [9](#cas13448-bib-0009){ref-type="ref"}, [10](#cas13448-bib-0010){ref-type="ref"}, [11](#cas13448-bib-0011){ref-type="ref"}, [12](#cas13448-bib-0012){ref-type="ref"} Therefore, we examined the level of glutamine uptake in SK‐LC‐17 transfectants. First, to measure the initial velocity of glutamine uptake in SK‐LC‐17 transfectants, we examined the time course of glutamine uptake in D‐13. We found that glutamine uptake into D‐8 occurred in a linear mode for the first 1 minute (Figure [S11](#cas13448-sup-0011){ref-type="supplementary-material"}). Next, we compared glutamine uptake among SK‐LC‐17 transfectants for the first 1 minute. Glutamine uptake was significantly different between GD2^+^ SK‐LC‐17 transfectants and GD2^−^ SK‐LC‐17 transfectants within initial linear phase, which suggested that initial velocities of glutamine uptake of GD2^+^ SK‐LC‐17 transfectants were higher than those of GD2^−^ SK‐LC‐17 transfectants (Figure [4](#cas13448-fig-0004){ref-type="fig"}A). Next, we examined roles of glutamine in the malignant phenotypes by using MTT assay to analyze cell proliferation. We found that cell proliferation was significantly increased in GD2^+^ SK‐LC‐17 transfectants in the presence of glutamine (Figure [4](#cas13448-fig-0004){ref-type="fig"}B). Cell proliferation was not detected without glutamine (data not shown).

![Malignant phenotypes were suppressed by ASC amino acid transporter 2 inhibitor L‐γ‐glutamyl‐p‐nitroanilide (GPNA). A, Glutamine uptake in SK‐LC‐17 transfectants treated with 1 mmol/L GPNA was measured using \[^3^H\]‐glutamine. Cells (2.0 × 10^5^) were treated with RPMI‐1640 supplemented with 1 nmol/L \[^3^H\]‐glutamine. After 1 min, the cells were washed with ice‐cold PBS three times and were lysed. Radioactivity was counted by a liquid scintillation counter. B, Cell proliferation was measured by MTT assay. Cells (2.0 × 10^3^) were plated in 96‐well plates and incubated for 1‐5 days in RPMI‐1640 (containing no glutamine) supplemented with 10% dialyzed FCS and glutamine (5 mmol/L). Cell growth rate was analyzed by using MTT reagent. Absorbance (590 nm) was determined and plotted in graphs. \**P* \< .05; \*\**P* \< .01. C, Cell proliferation of SK‐LC‐17 transfectants treated with GPNA was measured by MTT assay. Cells (2.0 × 10^3^) were plated in 96‐well plates and incubated for 1‐5 days in RPMI‐1640 supplemented with 10% dialyzed FCS and GPNA (0 mmol/L or 1 mmol/L). \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001. D, Cell migration of SK‐LC‐17 transfectants treated with GPNA was measured by wound healing assay. SK‐LC‐17 transfectants (2.0 × 10^6^) were scratched and washed twice. After 16 h, migration rates (migration area at 16‐0 h) were calculated. Scale bar = 100 μm. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001](CAS-109-141-g004){#cas13448-fig-0004}

To examine the function of ASCT2, we used GPNA, which specifically inhibits glutamine uptake by ASCT2.[11](#cas13448-bib-0011){ref-type="ref"}, [13](#cas13448-bib-0013){ref-type="ref"} Glutamine uptake was significantly decreased in SK‐LC‐17 transfectants by GPNA (Figure [4](#cas13448-fig-0004){ref-type="fig"}A). To clarify whether glutamine uptake was really regulated by ASCT2 in SK‐LC‐17 transfectants, we examined glutamine uptake in SK‐LC‐17 transfectants treated with anti‐ASCT2 siRNAs. We prepared three kinds of anti‐ASCT2 siRNAs (\#1, \#2, and \#3) and tested knockdown efficiency of ASCT2 in SK‐KC‐l7 transfectants. Transfection of anti‐ASCT2 siRNA \#3 suppressed ASCT2 expression with high efficiency (Figure [S12](#cas13448-sup-0012){ref-type="supplementary-material"}A). After knockdown with anti‐ASCT2 siRNA \#3, glutamine uptake into SK‐LC‐17 transfectants was significantly reduced (Figure [S12](#cas13448-sup-0012){ref-type="supplementary-material"}B,C). In GPNA‐treated cells, cell proliferation was significantly decreased (Figure [4](#cas13448-fig-0004){ref-type="fig"}C). In particular, GD2^+^ SK‐LC‐17 transfectants were more affected by GPNA and cell proliferation was more suppressed (Figure [4](#cas13448-fig-0004){ref-type="fig"}C), because glutamine uptake through ASCT2 is more enhanced in GD2^+^ SK‐LC‐17 transfectants due to increased expression levels of ASCT2 in GEM/rafts (Figures [4](#cas13448-fig-0004){ref-type="fig"}A, [S2](#cas13448-sup-0012){ref-type="supplementary-material"}). Furthermore, cell migration was significantly suppressed in GD2^+^ SK‐LC‐17 transfectants by GPNA (Figure [4](#cas13448-fig-0004){ref-type="fig"}D). These results indicate that GD2 enhances the function of ASCT2, and eventually the malignant properties of SK‐LC‐17 cells. These effects were brought about based on the co‐operation in GEM/rafts. However, the precise mechanisms by which GD2 enhances the function of ASCT2 remain to be investigated.

3.5. Mammalian target of rapamycin complex 1 signaling axis attenuated by reduction of glutamine uptake {#cas13448-sec-0026}
-------------------------------------------------------------------------------------------------------

Glutamine is a key amino acid to activate the mTORC1 signaling axis.[16](#cas13448-bib-0016){ref-type="ref"}, [17](#cas13448-bib-0017){ref-type="ref"} Therefore, we examined phosphorylation levels of downstream factors of mTORC1, such as p70 S6K1 and S6. SK‐LC‐17 transfectants were treated with GPNA to inhibit glutamine uptake by ASCT2. Consequently, p70 S6K1 and S6 were dephosphorylated in a time‐dependent manner in SK‐LC‐17 transfectants (Figure [5](#cas13448-fig-0005){ref-type="fig"}). Interestingly, p70 S6K1 and S6 of GD2^+^ SK‐LC‐17 transfectants were dephosphorylated faster than those in GD2^−^ SK‐LC‐17 transfectants. Hence, glutamine uptake through ASCT2 is more required in GD2^+^ SK‐LC‐17 cells for activation of the mTORC1 signaling axis.

![Mammalian target of rapamycin complex 1 (mTORC1) signaling axis attenuated by reduction of glutamine uptake. A, Phosphorylation levels of mTOR, S6K1, and S6 were analyzed by Western blotting. SK‐LC‐17 transfectants (8 × 10^5^) were incubated for 0, 12, 24, 36, and 48 h in RPMI‐1640 containing 1 mmol/L L‐γ‐glutamyl‐p‐nitroanilide (GPNA). B, Intensity of bands of phosphorylated mTOR, S6K1, and S6 was scanned; data are presented in graphs after correction with those of total mTOR, S6K1, and S6, respectively](CAS-109-141-g005){#cas13448-fig-0005}

These results suggested that glutamine uptake through ASCT2 leads to the activation of the mTORC1 signaling axis that is involved, at least partly, in the enhancement of cell proliferation and migration in GD2^+^ SK‐LC‐17 cells.

4. DISCUSSION {#cas13448-sec-0027}
=============

In order to develop novel treatments for cancer, it is essential to identify tumor‐specific molecules. Ganglioside GD2 is specifically expressed in SCLC cells, but hardly expressed in NSCLC cells or normal tissues.[3](#cas13448-bib-0003){ref-type="ref"} Previous studies reported that GD2 promoted malignant phenotypes, such as cell proliferation and invasion, and anti‐GD2 mAb induced apoptosis in SCLC cells.[3](#cas13448-bib-0003){ref-type="ref"}, [4](#cas13448-bib-0004){ref-type="ref"} However, it was not well known how GD2 works in SCLC cells. We addressed this issue focusing on SCLC in this study. Recently, it has been reported that the EMARS method is a novel way to identify molecules interacting with gangliosides.[21](#cas13448-bib-0021){ref-type="ref"}, [22](#cas13448-bib-0022){ref-type="ref"} For example, PDGFRα was identified as a GD3‐associating protein in glioma cells using the EMARS method.[19](#cas13448-bib-0019){ref-type="ref"} Moreover, neogenine, a membrane protein that promotes the development of the nervous system, was identified as a GD3‐associating molecule in melanoma cells. Neogenin enhanced malignant phenotypes in melanoma cells through its intracellular domain as a transcription factor.[20](#cas13448-bib-0020){ref-type="ref"} In this study, we undertook EMARS and MS to clarify how GD2 works and what kind of molecules GD2 works with in SCLC cells.

This study provided evidence for the first time that ganglioside interacts with an amino acid transporter. Results of EMARS‐MS suggested that several molecules were associated with GD2 on the cell surface. Among the candidate molecules, ASCT2 was specifically expressed in GEM/rafts of GD2^+^ SK‐LC‐17 transfectants (Figure [2](#cas13448-fig-0002){ref-type="fig"}A). Therefore, we identified ASCT2 as a representative molecule associating with GD2. Several transcription factors, such as activating transcription factor 4, N‐myc, and E2F3, promoted glutamine metabolism through ASCT2 in several tumors,[12](#cas13448-bib-0012){ref-type="ref"}, [28](#cas13448-bib-0028){ref-type="ref"}, [29](#cas13448-bib-0029){ref-type="ref"} and N‐myc and E2F3 were highly expressed in SCLC cells.[30](#cas13448-bib-0030){ref-type="ref"}, [31](#cas13448-bib-0031){ref-type="ref"} However, in this study, the total expression level of ASCT2 was not considerably different among SK‐LC‐17 transfectants (Figure [2](#cas13448-fig-0002){ref-type="fig"}B). Hence, GD2 did not seem to affect ASCT2 expression in SK‐LC‐17 cells. ASC amino acid transporter 2 contains two putative N‐linked glycosylation sites (N163 and N212), and ASCT2 is transported to the plasma membrane depending on N‐linked glycosylation.[32](#cas13448-bib-0032){ref-type="ref"} However, the expression levels of ASCT2 on the plasma membrane is the same among SK‐LC‐17 transfectants (Figure [S3](#cas13448-sup-0003){ref-type="supplementary-material"}). Taking membrane trafficking of ASCT2 and our results together, it might be true that GD2 does not recruit mature ASCT2 to the plasma membrane but to GEM/rafts. However, the trafficking mechanism of ASCT2 remains to be elucidated in detail. We found that GD2 bound with ASCT2 in GD2^+^ SK‐LC‐17 transfectants (Figures [2](#cas13448-fig-0002){ref-type="fig"}C,D, [S9](#cas13448-sup-0009){ref-type="supplementary-material"}), and GD2 was also closely associated with ASCT2 in NCI‐N417 and ACC‐LC‐171 cells (Figures [S8](#cas13448-sup-0008){ref-type="supplementary-material"}, [S10](#cas13448-sup-0010){ref-type="supplementary-material"}). Previously, it was reported that sialic acid‐containing GM3 bound with insulin receptor through lysine residue on the plasma membrane,[33](#cas13448-bib-0033){ref-type="ref"} indicating that a sialic acid of ganglioside binds with basic amino acids of membrane proteins. Interestingly, we found that three basic amino acids of ASCT2 located at the neighboring region of the plasma membrane, suggesting that GD2 might bind with ASCT2 through these three residues.

ASC amino acid transporter 2 is coexpressed with LAT1 (SLC7A5) in several tumors such as lung adenocarcinomas, leukemia, and tongue cancer, and the expression of both ASCT2 and LAT1 enhances malignant phenotypes of cancers in vitro and in vivo.[34](#cas13448-bib-0034){ref-type="ref"}, [35](#cas13448-bib-0035){ref-type="ref"}, [36](#cas13448-bib-0036){ref-type="ref"} The mechanism by which the combination of ASCT2 and LAT1 increases malignant phenotypes in cancer cells is considered to be due to activation of the mTORC1 signaling pathway. ASC amino acid transporter 2 and LAT1 are a major glutamine transporter and a major leucine transporter, respectively, and both of these amino acids activate the mTORC1 signaling pathway in an independent manner.[16](#cas13448-bib-0016){ref-type="ref"} Although the interaction between ASCT2 and LAT1 is poorly understood in SCLC cells, both transporters might co‐operate and activate the mTORC1 signaling axis. Our data and previous studies showed that glutamine uptake by ASCT2 activated the mTORC1 signaling axis, such as p70 S6K1 and S6.[37](#cas13448-bib-0037){ref-type="ref"} Recent studies elucidated that p70 S6K1 regulates cell migration and invasion in cancer cells.[38](#cas13448-bib-0038){ref-type="ref"}, [39](#cas13448-bib-0039){ref-type="ref"}, [40](#cas13448-bib-0040){ref-type="ref"} Moreover, p70 S6K1‐mediated phosphorylation controls phosphatidylinositol 4‐phosphate 5‐kinase type I degradation to regulate development of focal adhesions and invadopodia, and consequently, cell migration and invasion.[41](#cas13448-bib-0041){ref-type="ref"} In this study, GPNA decreased glutamine uptake by ASCT2 in SK‐LC‐17 transfectants, leading to inactivated signaling of p70 S6K1, and consequently to reduced cell migration (Figures [4](#cas13448-fig-0004){ref-type="fig"}D, [5](#cas13448-fig-0005){ref-type="fig"}A,B). These results suggest that glutamine regulates cell migration based on p70 S6K1-- phosphatidylinositol 4‐phosphate 5‐kinase type I in SK‐LC‐17 transfectants.

ASC amino acid transporter 2 is considered to be a novel target for treatment in several tumors,[8](#cas13448-bib-0008){ref-type="ref"}, [9](#cas13448-bib-0009){ref-type="ref"}, [10](#cas13448-bib-0010){ref-type="ref"}, [11](#cas13448-bib-0011){ref-type="ref"}, [12](#cas13448-bib-0012){ref-type="ref"} and several ASCT2 inhibitors have been developed. To examine whether anti‐GD2 mAb enhances the effect of ASCT2 inhibitors, such as GPNA and BenSer,[42](#cas13448-bib-0042){ref-type="ref"} in SCLC cells, we will perform dual administration of anti‐GD2 mAb and GPNA in vitro and in vivo, in SCLC cells and a xenograft model, respectively. GD2 is also a promising target for treatment of neuroblastoma, and anti‐GD2 mAb has been developed for therapy trials.[5](#cas13448-bib-0005){ref-type="ref"}, [43](#cas13448-bib-0043){ref-type="ref"}, [44](#cas13448-bib-0044){ref-type="ref"} However, little is known about how GD2 promotes malignant phenotypes in neuroblastoma cells. It has been reported that ASCT2 is also expressed in neuroblastoma cells, and promotes malignant phenotypes by glutamine uptake.[12](#cas13448-bib-0012){ref-type="ref"} GD2 might also interact with ASCT2 on the plasma membrane of neuroblastoma cells, leading to enhancement of malignant phenotypes. Recently, ADCs have been vigorously developed for oncology therapeutics.[45](#cas13448-bib-0045){ref-type="ref"} Gangliosides including GD2 are adequate antigen targets for ADCs, because several gangliosides are specifically expressed in tumor cells. Therefore, ADCs targeting gangliosides are thought to be effective therapeutics for tumors. The results of this study suggest that anti‐GD2 mAb conjugated with an ASCT2 inhibitor is an effective strategy for novel therapy towards SCLC cells and neuroblastoma cells.

In conclusion, we uncovered the roles of GD2 in SCLC cells in this study. GD2 recruits ASCT2 to GEM/rafts and enhances glutamine uptake through ASCT2 in SCLC cells. As a result, malignant phenotypes, such as cell proliferation and migration, were increased through activation of the mTORC1 signaling axis.
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